Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference
Pyxis Oncology (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics for difficult-to-treat cancers, has announced its participation in the Leerink Partners Global Healthcare Conference in Miami, Florida.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pyxis Oncology (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics for difficult-to-treat cancers, has announced its participation in the Leerink Partners Global Healthcare Conference in Miami, Florida.
The company's President and CEO, Dr. Lara S. Sullivan, will engage in a fireside chat scheduled for March 10, 2025, at 2:20 PM EST. Investors and interested parties can access both the live webcast and replay of the presentation through the Events & Presentations page in the Investor Relations section of Pyxis Oncology's website at ir.pyxisoncology.com.
Details
News Market Reaction – PYXS
The recorded move for PYXS in the trading session of this news was -6.72%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Monday, March 10, 2025 at 2:20 PM EST at the Leerink Partners Global Healthcare Conference in Miami, Florida.
A live webcast and replay of the fireside chat will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website, ir.pyxisoncology.com.
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The company is efficiently building next generation therapeutics that hold the potential for monotherapy and combination indications. PYX-201, an antibody-drug conjugate (ADC) that uniquely targets EDB+FN, a non-cellular structural component of the tumor extracellular matrix, is being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors. PYX-201 is designed to directly kill cancer cells and to address factors in the microenvironment that enable the uncontrolled proliferation and immune evasion of malignant tumors.
To learn more, visit www.pyxisoncology.com or follow us on X (formerly known as Twitter) and LinkedIn.
Pyxis Oncology Contact
Pamela Connealy
CFO and COO
ir@pyxisoncology.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.